484 related articles for article (PubMed ID: 29524617)
1. Progress in the Management of Malignant Pleural Mesothelioma in 2017.
McCambridge AJ; Napolitano A; Mansfield AS; Fennell DA; Sekido Y; Nowak AK; Reungwetwattana T; Mao W; Pass HI; Carbone M; Yang H; Peikert T
J Thorac Oncol; 2018 May; 13(5):606-623. PubMed ID: 29524617
[TBL] [Abstract][Full Text] [Related]
2. Is there a role for immunotherapy in malignant pleural mesothelioma?
Tartarone A; Lerose R; Aieta M
Med Oncol; 2018 May; 35(7):98. PubMed ID: 29845408
[TBL] [Abstract][Full Text] [Related]
3. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Phillips MM; Pavlyk I; Allen M; Ghazaly E; Cutts R; Carpentier J; Berry JS; Nattress C; Feng S; Hallden G; Chelala C; Bomalaski J; Steele J; Sheaff M; Balkwill F; Szlosarek PW
Pharmacol Rep; 2023 Jun; 75(3):570-584. PubMed ID: 37010783
[TBL] [Abstract][Full Text] [Related]
4. New therapeutic strategies for malignant pleural mesothelioma.
Bonelli MA; Fumarola C; La Monica S; Alfieri R
Biochem Pharmacol; 2017 Jan; 123():8-18. PubMed ID: 27431778
[TBL] [Abstract][Full Text] [Related]
5. Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma.
Gray SG
BMC Pulm Med; 2021 May; 21(1):148. PubMed ID: 33952230
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.
Wong RM; Ianculescu I; Sharma S; Gage DL; Olevsky OM; Kotova S; Kostic MN; Grundfest WS; Hou D; Cameron RB
Am J Respir Cell Mol Biol; 2014 May; 50(5):870-5. PubMed ID: 24450537
[TBL] [Abstract][Full Text] [Related]
7. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
[TBL] [Abstract][Full Text] [Related]
8. Advances in treatment of mesothelioma.
Maggioni C; Barletta G; Rijavec E; Biello F; Gualco E; Grossi F
Expert Opin Pharmacother; 2016 Jun; 17(9):1197-205. PubMed ID: 27055148
[TBL] [Abstract][Full Text] [Related]
9. Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy.
Murthy V; Katzman D; Sterman DH
Clin Respir J; 2019 May; 13(5):272-279. PubMed ID: 30810270
[TBL] [Abstract][Full Text] [Related]
10. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
[TBL] [Abstract][Full Text] [Related]
11. The minimum standard of care for managing malignant pleural mesothelioma in developing nations within the Asia-Pacific Region.
Ke H; Kao S; Lee K; Takahashi K; Goh HP; Linton A
Asia Pac J Clin Oncol; 2022 Jun; 18(3):177-190. PubMed ID: 34161674
[TBL] [Abstract][Full Text] [Related]
12. Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression.
Marcq E; Audenaerde JRV; Waele J; Jacobs J; Loenhout JV; Cavents G; Pauwels P; Meerbeeck JPV; Smits EL
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31455014
[TBL] [Abstract][Full Text] [Related]
13. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
14. Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
Szlosarek PW; Steele JP; Nolan L; Gilligan D; Taylor P; Spicer J; Lind M; Mitra S; Shamash J; Phillips MM; Luong P; Payne S; Hillman P; Ellis S; Szyszko T; Dancey G; Butcher L; Beck S; Avril NE; Thomson J; Johnston A; Tomsa M; Lawrence C; Schmid P; Crook T; Wu BW; Bomalaski JS; Lemoine N; Sheaff MT; Rudd RM; Fennell D; Hackshaw A
JAMA Oncol; 2017 Jan; 3(1):58-66. PubMed ID: 27584578
[TBL] [Abstract][Full Text] [Related]
15. BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification.
Barnett SE; Kenyani J; Tripari M; Butt Z; Grosman R; Querques F; Shaw L; Silva LC; Goate Z; Marciniak SJ; Rassl DM; Jackson R; Lian LY; Szlosarek PW; Sacco JJ; Coulson JM
Mol Cancer Res; 2023 May; 21(5):411-427. PubMed ID: 36669126
[TBL] [Abstract][Full Text] [Related]
16. Current efforts in research of pleural mesothelioma-An analysis of the ClinicalTrials.gov registry.
Süveg K; Putora PM; Berghmans T; Glatzer M; Kovac V; Cihoric N
Lung Cancer; 2018 Oct; 124():12-18. PubMed ID: 30268449
[TBL] [Abstract][Full Text] [Related]
17. [Chinese guideline for clinical diagnosis and treatment of malignant pleural mesothelioma (2021 Edition)].
Multidisciplinary Committee of Oncology, Chinese Physicians Association
Zhonghua Zhong Liu Za Zhi; 2021 Apr; 43(4):383-394. PubMed ID: 33902201
[TBL] [Abstract][Full Text] [Related]
18. Emerging biological therapies for the treatment of malignant pleural mesothelioma.
Davis AP; Kao SC; Clarke SJ; Boyer M; Pavlakis N
Expert Opin Emerg Drugs; 2021 Jun; 26(2):179-192. PubMed ID: 33945357
[No Abstract] [Full Text] [Related]
19. Updates in the diagnosis and treatment of malignant pleural mesothelioma.
Katzman D; Sterman DH
Curr Opin Pulm Med; 2018 Jul; 24(4):319-326. PubMed ID: 29553973
[TBL] [Abstract][Full Text] [Related]
20. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.
Bograd AJ; Suzuki K; Vertes E; Colovos C; Morales EA; Sadelain M; Adusumilli PS
Cancer Immunol Immunother; 2011 Nov; 60(11):1509-27. PubMed ID: 21913025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
